{"commentary":{"count":289,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":104,"youtube":100,"podcast":81,"x_video":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03274492\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"POLARIX","nct_id":"NCT03274492","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=polarix-nct03274492. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"POLARIX","arms":[{"description":"Participants will receive polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) intravenously (IV), placebo for vincristine IV, rituximab 375 milligrams per square meter (mg/m\\^2) IV, cyclophosphamide 750 mg/m\\^2 IV, and doxorubicin 50 mg/m\\^2 IV on Day 1 and prednisone 100 milligrams per day (mg/day) orally (PO) on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m\\^2 IV will be administered as monotherapy in Cycles 7 and 8.","label":"R-CHP plus Vincristine Placebo plus Polatuzumab Vedotin","type":"EXPERIMENTAL"},{"description":"Participants will receive placebo for polatuzumab vedotin, rituximab 375 mg/m\\^2 IV, cyclophosphamide 750 mg/m\\^2 IV, doxorubicin 50 mg/m\\^2 IV, and vincristine 1.4 mg/m\\^2 IV (maximum 2 milligrams per dose \\[mg/dose\\]) on Day 1 and prednisone 100 mg/day PO on Days 1-5 of every 21-day cycle for 6 cycles. Rituximab 375 mg/m\\^2 IV will be administered as monotherapy in Cycles 7 and 8.","label":"R-CHOP plus Polatuzumab Vedotin Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-04-30","type":"ACTUAL"},"conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":{"count":1000,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Polatuzumab Vedotin","type":"DRUG"},{"name":"Rituximab","type":"DRUG"},{"name":"Cyclophosphamide","type":"DRUG"},{"name":"Doxorubicin","type":"DRUG"},{"name":"Vincristine","type":"DRUG"},{"name":"Vincristine Placebo","type":"DRUG"},{"name":"Prednisone","type":"DRUG"},{"name":"Polatuzumab vedotin Placebo","type":"DRUG"}],"last_update":"2026-05-08","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2026-04-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant Lymphoma","timeFrame":"From randomization to the first occurrence of disease progression or relapse, or death from any cause, whichever occurs earlier (up to 38 months)"}],"references":[{"citation":"Morschhauser F, Lenz G, Herrera AF, Flowers CR, Trneny M, Burke JM, Hou JZ, Staber PB, Hawkes EA, Izutsu K, Le Gouill S, Belada D, Tucci A, Yan M, Harris W, Lu K, Bolen CR, Hirata J, Lee C, Jiang Y, Jardin F, Hatzi K. Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP- but not Pola-R-CHP-treated patients with DLBCL. Blood Neoplasia. 2026 Jul 2;3(4):100264. doi: 10.1016/j.bneo.2026.100264. eCollection 2026 Nov.","pmid":"42699559","type":"DERIVED"},{"citation":"Thompson C, Trneny M, Morschhauser F, Salles G, Reagan PM, Hertzberg M, Zhang H, Thieblemont C, Hu B, Fonseca G, Kim WS, Martelli M, Mehta A, Singh A, Yan M, Hirata J, Sugidono M, Lee C, Sharman JP, Mehta-Shah N, Flowers CR, Tilly H, Chua N, Casasnovas RO, Miall F, Kim TM, Tsai XC, Nasta S, Lee ST, Friedberg JW. PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study. Blood. 2026 Jan 15;147(3):254-265. doi: 10.1182/blood.2025028848.","pmid":"40997297","type":"DERIVED"},{"citation":"Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trneny M, Lenz G, Sharman JP, Herbaux C, Burke JM, Matasar M, Collins GP, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Pinto A, Rai S, Izutsu K, Greil R, Mykhalska L, Bergua-Burgues JM, Cheung MC, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Jiang Y, McCall B, Chohan S, Sugidono M, Yan M, Batlevi CL, Tilly H, Flowers CR. Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2025 Dec 10;43(35):3698-3705. doi: 10.1200/JCO-25-00925. Epub 2025 Sep 24.","pmid":"40991874","type":"DERIVED"},{"citation":"Hu B, Reagan PM, Sehn LH, Sharman JP, Hertzberg M, Zhang H, Kim A, Herbaux C, Molina L, Maruyama D, Stenner F, Chohan S, Kothari R, Lee Batlevi C, Hirata J, Sahin D, Lee C, Sugidono M, Tilly H. Subgroup analysis of older patients >/=60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study. Blood Adv. 2025 May 27;9(10):2489-2499. doi: 10.1182/bloodadvances.2024014707.","pmid":"40085955","type":"DERIVED"},{"citation":"Liao MZ, Deng R, Gibiansky L, Lu T, Agarwal P, Dere R, Lee C, Hirata J, Herbaux C, Salles G, Li C, Miles D. Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non-Asian patients with previously untreated diffuse large B-cell lymphoma in POLARIX. Clin Transl Sci. 2023 Dec;16(12):2744-2755. doi: 10.1111/cts.13669. Epub 2023 Oct 31.","pmid":"37864313","type":"DERIVED"},{"citation":"Song Y, Tilly H, Rai S, Zhang H, Jin J, Goto H, Terui Y, Shin HJ, Kim WS, Cao J, Feng J, Eom HS, Kim TM, Tsai XC, Gau JP, Koh H, Zhang L, Song Y, Yang Y, Li W, Huang H, Ando K, Sharman JP, Sehn LH, Bu L, Wang X, Jiang Y, Hirata J, Lee C, Zhu J, Izutsu K. Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial. Blood. 2023 Apr 20;141(16):1971-1981. doi: 10.1182/blood.2022017734.","pmid":"36626583","type":"DERIVED"},{"citation":"Varma G, Wang J, Diefenbach C. Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma. Expert Rev Anticancer Ther. 2022 Aug;22(8):795-803. doi: 10.1080/14737140.2022.2093191. Epub 2022 Jun 27.","pmid":"35726803","type":"DERIVED"},{"citation":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgues JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14.","pmid":"34904799","type":"DERIVED"}],"start_date":{"date":"2017-11-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma","url":"https://clinicaltrials.gov/study/NCT03274492"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/polarix-nct03274492"}